Академический Документы
Профессиональный Документы
Культура Документы
Investor Presentation
Annual Meeting of Stockholders
June 2, 2011
© 2011 Cardium Therapeutics, Inc.
Forward Looking Statement
2
© 2011 Cardium Therapeutics, Inc.
© 2011 Cardium Therapeutics, Inc.
Cardium is pioneering the development of a new asset investment class now termed
“enterprise capital.” The Company is focused on the acquisition and strategic development of
product opportunities and businesses having the potential to address significant unmet
medical needs, and definable pathways to commercialization, synergistic sale, partnering
and other monetizations following the achievement of corresponding development objectives
and economic valuation inflection points. The Company’s first generation investment portfolio
included Innercool Therapies, the Tissue Repair Company and Cardium Biologics. 3
Wound Healing Health & Wellness Cardiovascular
Excellarate™ Nutra-Apps™
Linee™
Excellagen™ Cerex™ Generx®
© 2011 Cardium Therapeutics, Inc.
Osteorate™ Relapril*
Corgentin™
Periorate™ Alena*
Energy*
Skin Care Optium*
*under development
4
Investment Highlights
Capital-efficient business strategy focused on finding “diamonds in the rough” and leveraging
research and development investments by big pharma, venture and institutional investors │
Strategy intended to provide a diversified and more balanced portfolio of risk/return opportunities
Generx Global Cardiovascular Platform: Targeting Russia (and CIS) for initial commercialization
based on planned registration study that is now pending health authority review │ Medical focus:
Patients with advanced coronary artery disease who have limited access to costly and rationalized
bypass surgery and angioplasty / stent procedures (Russian CVD death rates 5X greater than U.S.;
average life expectancy for males – 57 years)
Excellagen Wound Care Management Platform: Initial product has pending FDA 510(k) submission
for marketing and sales clearance which is targeted for 2011 market launch │ Other product line
extensions currently under consideration
Key Investor Metrics: No outstanding debt, substantial trading liquidity, continuing news
flow expected │ Current capital structure provides for significant economic upside potential
as CXM executes business strategy
Highly-focused, experienced and multi-disciplined management team that plays a very active role
in strategic planning and daily operations for CXM’s technology and businesses portfolio 5
New Corporate
& Strategic
Leadership
Catalytic Access to
Agent of Strategic
Change Capital
© 2011 Cardium Therapeutics, Inc.
© 2011 Cardium Therapeutics, Inc.
Fresh Ideas,
New Technologies
& Product
Opportunities
6
Cardium’s Strategic Acquisition Focus
© 2011 Cardium Therapeutics, Inc.
© 2011 Cardium Therapeutics, Inc.
DNA-Based Adenovector
Biologics, Product
Portfolio, Manufacturing
& Technology Platforms
Cardium Biologics: Overview
9
Regenerative Medicine:
Product Portfolio Focus
Wound
Healing
Periodontal
© 2011 Cardium Therapeutics, Inc.
Cardiovascular
Orthopedic
10
Russian Federation Regenerative Medicine:
DNA-Based Biologic Product Portfolio and
Manufacturing / Technology Platform
Commercial
Product Disease Medical Mechanism
Formulation & Clinical
Name Focus Indication of Action
Status
Initiating
Generx® Phase 3 / Heart Myocardial
Ad5-FGF4 Angiogenesis
(Cardionovo) Registration Disease Ischemia
Study in Russia
U.S. Phase 2
Completed; Diabetic
Wound Tissue
Excellerate™ Ad5-PDGFB Foot
Planning Healing Regeneration
Ulcers
Phase 3 Study
Pre-Clinical
Ad5-PDGFB Bone Fractures Bone
Osteorate™ Validations Orthopedics
AdBMP-4 Spinal Fusion Regeneration
Completed
Pre-Clinical Periodontal
Periodontal
Periorate™ Ad5-PDGFB Validations Dental Tissue
© 2011 Cardium Therapeutics, Inc.
Disease
Completed Regeneration
Cardiac
Pre-Clinical Heart Myocardial
Corgentin™ Ad5-IGF1 Tissue
Study Attack Infarction
Repair
11
Generx [Ad5FGF-4]
Cardionovo
12
Therapeutic Positioning: Generx / Cardionovo
(PTCA)
Percutaneous
Traditional Transluminal
Drug Balloon
Therapy Angioplasty
& Stents
Coronary
Artery
Disease
Generx®
(CABG) Non-Surgical
Coronary DNA-Based
© 2011 Cardium Therapeutics, Inc.
13
Generx [Ad5-FGF4]
Catheter-Based Angiogenic
Intracoronary Delivery Microvascular Circulation
© 2011 Cardium Therapeutics, Inc.
14
The Therapeutic Process of
Cardiac Microvascular Angiogenesis
Generx has been evaluated in studies of over 650 patients (including 450
Generx-treated patients) in four multi-center, double-blind, placebo-controlled
clinical studies at 100 medical centers. Generx is the most clinically advanced
DNA-based cardiovascular angiogenic growth factor therapeutic in the world.
One-Time Treatment
DNA-Based Delivery
Generx Ad5FGF-4
© 2011 Cardium Therapeutics, Inc.
(alferminogene tadenovec)
Angiogenic Response
AGENT-2 - Representative Generx-treated patient: 77% SPECT
improvement in cardiac perfusion at 8 weeks equivalent
to bypass surgery and PCI (angioplasty/stenting) at one year.
15
Potential Cardiovascular Product:
Illustrative Metrics
At Potential
Annual Unit $2,000 / dose $3,000 / dose $4,000 / dose $5,000 / dose
Volume of:
50,000 doses $100 Million $150 Million $200 Million $250 Million
100,000 doses $200 Million $300 Million $400 Million $500 Million
150,000 doses $300 Million $450 Million $600 Million $750 Million
200,000 doses $400 Million $600 Million $800 Million $1.0 Billion
© 2011 Cardium Therapeutics, Inc.
16
Excellagen: A New Synergistic Treatment
Option for Surgical Debridement Procedures
Healing for
Diabetic Foot Ulcers
Wound Care
Management Standard
of Care: Living Skin
Platform Dressings & Equivalents
Bandages
Diabetic
Foot
Ulcers
Excellarate™ Negative
[Ad5PDGF-B] Pressure Topical
Vacuum Gel
Formulated Pumps
Collagen-Based
© 2011 Cardium Therapeutics, Inc.
18
The Biology of Wound Healing
© 2011 Cardium Therapeutics, Inc.
19
Wound Care Management Platform
Formulated-Collagen Topical Gel
X Highly-refined Fibrillar
Type I Bovine Collagen
X Structural Stabilizers,
Hydrolytic Enzyme
Inhibitors, and
Bacteriostatic agents added
X Initially for
Professional Use
X Pre-Formulated Plug-N-Play
X Refrigerated Storage
20
Excellagen Matrix Clinical Study
Results Accepted for Publication by
Peer-Reviewed Journal
21
Matrix Phase 2b Clinical Study
Healing Response:
Reduction in Wound Size Radius
0.25 cm
0.25 cm
(n = 47) (n = 47)
EXCELLAGEN
0.213
EXCELLAGEN
SOC 0.137
0.078 SOC
0.063
0 cm
(p = 0.018) 0 cm
(p = 0.032)
© 2011 Cardium Therapeutics, Inc.
Age 48
Sex Male
Age 43
© 2011 Cardium Therapeutics, Inc.
Sex Female
Surgical Procedure
Prior Therapy
to Remove Toes
Nutraceutical
Formulation
X
Pharmaceutical Millennial
Philosophy Target Market
© 2011 Cardium Therapeutics, Inc.
26
CONFIDENTIAL
Consumer
Wellness Measures Response
27
CONFIDENTIAL
MedPodium marketing emphasizes these four factors in credible, jargon-free messaging that
attracts the discerning, highly connected Millennial.
28
CONFIDENTIAL
29
CONFIDENTIAL
Cerex: Cognitive support for today’s focus, attention and memory needs.
Millennials are known for a relentless pursuit of their passions, which
can demand long periods of concentrated focus. Cerex offers a safe,
natural alternative for college students and working professionals who
need to enhance their cognitive performance. Typical Millennial
outtakes for Cerex:
“My world doesn’t fit into 9-5. Cerex keeps me going.”
“When I need to crank through the night, Cerex helps me
stay focused.”
30
CONFIDENTIAL
Demographic Values
Driven: Driven:
Millennials “Modern”
(20 – 35) Consumers
(20 – 70)
31
CONFIDENTIAL
Supplement Industry
Market Opportunity
U.S.
Areas of Initial Focus Annual Percent
Sales
32
© 2011 Cardium Therapeutics, Inc.